|
INTRODUCTION |
2 |
|
OUR STORY |
2 |
|
HIGHLIGHTS FOR THE YEAR |
3 |
|
ABOUT THIS REPORT |
5 |
|
REPORTING SUITE |
6 |
|
NAVIGATION |
6 |
|
FORWARD LOOKING STATEMENTS |
7 |
|
OUR BUSINESS |
9 |
|
ORGANISATIONAL OVERVIEW |
11 |
|
COMPANY HISTORY |
12 |
|
VISION MISSION AND STRATEGY |
13 |
|
GROUP STRUCTURE |
14 |
|
OUR FOOTPRINT |
15 |
|
OUR LEADERSHIP |
17 |
|
BOARD OF DIRECTORS |
20 |
|
EXECUTIVE COMMITTEE |
22 |
|
CHAIRPERSONS REPORT |
24 |
|
CHIEF EXECUTIVE OFFICERS REPORT |
28 |
|
STRATEGY |
31 |
|
STRATEGY |
33 |
|
BUSINESS MODEL |
38 |
|
STAKEHOLDER ENGAGEMENT |
44 |
|
MATERIAL RISKS AND OPPORTUNITIES |
49 |
|
PERFORMANCE OVERVIEW |
55 |
|
CHIEF FINANCIAL OFFICERS REPORT |
57 |
|
GROUP RESULTS AT A GLANCE |
61 |
|
GROUP ANNUAL FINANCIAL STATEMENTS (SUPPLEMENTARY INFORMATION) |
62 |
|
OPERATIONAL REVIEWS |
65 |
|
MEDSCHEME SOUTH AFRICA |
67 |
|
AID FOR AIDS |
70 |
|
AFROCENTRIC HEALTH SOLUTIONS |
71 |
|
HELIOS IT SOLUTIONS |
73 |
|
ALLEGRA |
75 |
|
PHARMACY DIRECT CURASANA AND ACTIVO HEALTH |
77 |
|
KLINIKKA |
79 |
|
GOVERNANCE AND SUSTAINABILITY |
81 |
|
CORPORATE GOVERNANCE REPORT |
83 |
|
REMUNERATION COMMITTEE REPORT |
92 |
|
SOCIAL AND ETHICS COMMITTEE REPORT |
95 |
|
SHAREHOLDER INFORMATION |
105 |
|
FINANCIAL CALENDAR |
104 |
|
NOTICE OF ANNUAL GENERAL MEETING |
108 |
|
FORM OF PROXY |
117 |
|
APPENDIX – EXTRACT FROM SECTION 58 OF THE COMPANIES ACT |
119 |
|
ANNEXURE A – MEMORANDUM OF INCORPORATION AMENDMENT |
120 |
|
GLOSSARY |
134 |
|
ADMINISTRATION AND CONTACT INFORMATION |
135 |


